Imaging with 68Ga-NY104 for detecting renal cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to evaluate the effectiveness of 68Ga-NY104 PET/CT imaging in identifying clear cell renal cell carcinoma (ccRCC) in patients. It will recruit two groups of participants: those scheduled for surgical removal of renal masses and those with confirmed or suspected recurrent ccRCC. Each participant will receive a single intravenous dose of 68Ga-NY104, followed by whole-body PET/CT imaging to assess the imaging's sensitivity and specificity. The study will be conducted at Peking Union Medical College Hospital, adhering to ethical guidelines and regulations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent provided for participation in the trial
2. Age ≥ 18 y
3. at least one of the following indications should be applied

   1. Scheduled for surgical resection of renal mass
   2. confirmed recurrent/metastatic clear cell renal cell carcinoma
   3. suspicion for recurrent/metastatic clear cell renal cell carcinoma

Exclusion Criteria:

1. On VEGF TKI treatment less than 1 week before 68Ga-NY104 PET/CT.
2. Pregnancy or lactation
3. Severe claustrophobia.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing, China Recruiting

Study contacts

• Principal investigator: Huo Li, MD — Peking Uion Medical College Hospital
• Study coordinator: Huo Li, MD
• Email: huoli@pumch.cn
• Phone: 18612672038

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Who’s at high risk after RCC surgery? Real-world clues from French registry

  This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07753343

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.